Core Insights - The pharmaceutical and biotechnology index experienced a decline of 0.64% during the week, underperforming the Shanghai Composite Index by 1.34 percentage points, ending a two-week upward trend [4] - The National Healthcare Security Administration released the 2025 National Basic Medical Insurance Drug List, which included 114 products, achieving a success rate of 88% in negotiations, the highest in recent years [5] - The launch of the commercial health insurance innovative drug list included 19 drugs, complementing the basic medical insurance list and indicating a shift towards a multi-tiered healthcare system in China [5][19] Weekly Market Performance - The A-share market saw significant gains for Haiwang Bio, which rose by 71.20%, while Zhongsheng Pharmaceutical increased by 15.56% [2] - In the Hong Kong market, Jinxin Reproductive Medicine and Boan Biotechnology saw increases of 7.53% and 8.62%, respectively [2] Clinical Trials and Innovations - Kangfang Biopharma's dual-antibody drug, Kadunilumab, has initiated a Phase II clinical trial for esophageal squamous cell carcinoma, a prevalent cancer type in China [13][14] - A clinical trial for a gout treatment, polyethylene glycol-uricase injection (HZBio1), has also commenced, targeting patients with poorly controlled uric acid levels [17][18] New Drug Developments - Baoyi Pharmaceutical's stock surged nearly 140% on its first trading day, with a market capitalization of HKD 20.5 billion, despite a significant net loss of CNY 183 million in the first half of 2025 [6][7] - The company has 12 self-developed products, with SJ02 being the first long-acting FSH-CTP product approved in China [7] Industry Trends - The trend of "innovation + internationalization" remains a core direction for the pharmaceutical sector, supported by policies and increasing global competitiveness [5] - The demand for more effective and safer uric acid-lowering drugs is rising due to the increasing prevalence of gout, particularly among younger populations in China [18]

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on December 10, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Companies with Significant Buybacks - Tencent Holdings (00700) repurchased 1.06 million shares for a total of 636 million, representing 0.961% of its total share capital [2] - Xiaomi Group-W (01810) repurchased 2.4 million shares for 101 million, accounting for 0.400% of its total share capital [2] - China Feihe (06186) repurchased 5.47 million shares for 22.94 million, which is 2.521% of its total share capital [2] Group 2: Other Notable Buybacks - Geely Automobile (00175) repurchased 1.54 million shares for 27.14 million, representing only 0.047% of its total share capital [2] - Kweichow Moutai (600519) repurchased 204,000 shares for 8.82 million, which is 0.180% of its total share capital [2] - Vitasoy International (00345) repurchased 404,000 shares for 2.67 million, accounting for 2.180% of its total share capital [2] Group 3: Companies with Lower Buyback Amounts - 康臣药业 (01681) repurchased 354,000 shares for 5.28 million, which is 15.048% of its total share capital [2] - 瑞声科技 (02018) repurchased 150,000 shares for 5.76 million, representing 0.492% of its total share capital [2] - 周黑鸭 (01458) repurchased 160,500 shares for 2.68 million, which is 1.407% of its total share capital [3]

Core Viewpoint - Southbound funds increased their holdings in Jinxin Fertility (01951.HK) by 4.53 million shares on December 10, indicating a positive sentiment towards the company despite recent fluctuations in trading volume [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds reduced their holdings on 4 days, with a total net reduction of 16.03 million shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 14 days, resulting in a total net increase of 18.23 million shares [1] - Currently, southbound funds hold 1.465 billion shares of Jinxin Fertility, accounting for 53.1% of the company's total issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, ambulatory surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [1] - Jinxin Fertility operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [1]

Core Viewpoint - Jinxin Fertility (01951.HK) announced a share buyback on December 10, 2023, spending HKD 4.766 million to repurchase 1.926 million shares at a price range of HKD 2.43 to 2.49 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 1.926 million shares at a total cost of HKD 4.766 million [1] - The repurchase price per share ranged from HKD 2.43 to HKD 2.49 [1]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Company Actions - The company plans to repurchase 1,925,500 shares at a total cost of HKD 4.766 million [1]

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan, intending to repurchase 1.9255 million shares at a cost of HKD 4.766 million [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 錦欣生殖醫療集團有限公司 呈交日期： 2025年12月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不 ...

Core Viewpoint - Jinxin Reproductive (01951) announced a share buyback plan, indicating confidence in its stock value and potential for future growth [2] Group 1: Share Buyback Details - The company plans to repurchase 3.802 million shares at a total cost of HKD 9.2077 million [2] - The buyback price per share is set between HKD 2.4 and HKD 2.5 [2]

Core Viewpoint - Southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 11.989 million shares on December 9, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 24.8715 million shares [1] - Over the past 20 trading days, there have been 13 days of net increases in holdings by southbound funds, totaling a net increase of 9.3238 million shares [1] - Currently, southbound funds hold 1.46 billion shares of Jinxin Fertility, accounting for 52.94% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - Jinxin Fertility operates mainly in China and the United States [1]

Core Viewpoint - The company, Jinxin Fertility (01951), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 3.802 million shares at a total cost of HKD 9.2077 million [1] - The buyback price per share is set between HKD 2.4 and HKD 2.5 [1]